|
1
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L,
Ye XP, Peng T, Xie GS and Li LQ: Hepatic resection associated with
good survival for selected patients with intermediate and
advanced-stage hepatocellular carcinoma. Ann Surg. 260:329–340.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhong JH, Rodriguez AC, Ke Y, Wang YY,
Wang L and Li LQ: Hepatic resection as a safe and effective
treatment for hepatocellular carcinoma involving a single large
tumor, multiple tumors, or macrovascular invasion. Medicine
(Baltimore). 94:e3962015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sohn W, Paik YH, Kim JM, Kwon CH, Joh JW,
Cho JY, Gwak GY, Choi MS, Lee JH, Koh KC, et al: HBV DNA and HBsAg
levels as risk predictors of early and late recurrence after
curative resection of HBV-related hepatocellular carcinoma. Ann
Surg Oncol. 21:2429–2435. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu JC, Huang YH, Chau GY, Su CW, Lai CR,
Lee PC, Huo TI, Sheen IJ, Lee SD and Lui WY: Risk factors for early
and late recurrence in hepatitis B-related hepatocellular
carcinoma. J Hepatol. 51:890–897. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
European Association for Study of Liver;
European Organisation for and Research and Treatment of Cancer:
EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. Eur J Cancer. 48:599–641. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
National Comprehensive Cancer Network.
NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary
Cancers version 2. 2015.
|
|
8
|
Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ,
Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW and Yoon JH: Adjuvant
immunotherapy with autologous cytokine-induced killer cells for
hepatocellular carcinoma. Gastroenterology. 148:1383–1391. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng Z, Liang W, Wang D, Schroder PM, Ju
W, Wu L, Zheng Z, Shang Y, Guo Z and He X: Adjuvant chemotherapy
for patients with primary hepatocellular carcinoma: A
meta-analysis. Int J Cancer. 136:E751–E759. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhong JH, Ma L and Li LQ: Postoperative
therapy options for hepatocellular carcinoma. Scand J
Gastroenterol. 49:649–661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng AL, Amarapurkar D, Chao Y, Chen PJ,
Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, et al:
Re-evaluating transarterial chemoembolization for the treatment of
hepatocellular carcinoma: Consensus recommendations and review by
an international expert panel. Liver Int. 34:174–183. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ren ZG, Lin ZY, Xia JL, Ye SL, Ma ZC, Ye
QH, Qin LX, Wu ZQ, Fan J and Tang ZY: Postoperative adjuvant
arterial chemoembolization improves survival of hepatocellular
carcinoma patients with risk factors for residual tumor: A
retrospective control study. World J Gastroenterol. 10:2791–2794.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nonami T, Isshiki K, Katoh H, Kishimoto W,
Harada A, Nakao A and Takagi H: The potential role of postoperative
hepatic artery chemotherapy in patients with high-risk hepatomas.
Ann Surg. 213:222–226. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhong JH and Li LQ: Postoperative adjuvant
transarterial chemoembolization for participants with
hepatocellular carcinoma: A meta-analysis. Hepatol Res. 40:943–953.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen X, Zhang B, Yin X, Ren Z, Qiu S and
Zhou J: Lipiodolized transarterial chemoembolization in
hepatocellular carcinoma patients after curative resection. J
Cancer Res Clin Oncol. 139:773–781. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang JH, Guo Z, Lu HF, Wang XB, Yang HJ,
Yang FQ, Bao SY, Zhong JH, Li LQ, Yang RR and Xiang BD: Adjuvant
transarterial chemoembolization after curative resection of
hepatocellular carcinoma: Propensity score analysis. World J
Gastroenterol. 21:4627–4634. 2015.PubMed/NCBI
|
|
17
|
Zhong JH, Xiang BD and Li LQ: Letter: Pre-
and post-operative anti-viral therapy is important for patients
with hepatitis B virus-related hepatocellular carcinoma. Aliment
Pharmacol Ther. 41:789–790. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu
MS and Lin JT: Association between nucleoside analogues and risk of
hepatitis B virus-related hepatocellular carcinoma recurrence
following liver resection. JAMA. 308:1906–1914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yin J, Li N, Han Y, Xue J, Deng Y, Shi J,
Guo W, Zhang H, Wang H, Cheng S and Cao G: Effect of antiviral
treatment with nucleotide/nucleoside analogs on postoperative
prognosis of hepatitis B virus-related hepatocellular carcinoma: A
two-stage longitudinal clinical study. J Clin Oncol. 31:3647–3655.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX,
Shen F, Zhou WP and Wu MC: Antiviral therapy improves postoperative
survival in patients with hepatocellular carcinoma: A randomized
controlled trial. Ann Surg. 261:56–66. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Su CW, Chiou YW, Tsai YH, Teng RD, Chau
GY, Lei HJ, Hung HH, Huo TI and Wu JC: The influence of hepatitis B
viral load and pre-s deletion mutations on post-operative
recurrence of hepatocellular carcinoma and the tertiary preventive
effects by anti-viral therapy. PLoS One. 8:e664572013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chan AC, Chok KS, Yuen WK, Chan SC, Poon
RT, Lo CM and Fan ST: Impact of antiviral therapy on the survival
of patients after major hepatectomy for hepatitis B virus-related
hepatocellular carcinoma. Arch Surg. 146:675–681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ke Y, Ma L, You XM, Huang SX, Liang YR,
Xiang BD, Li LQ and Zhong JH: Antiviral therapy for hepatitis B
virus-related hepatocellular carcinoma after radical hepatectomy.
Cancer Biol Med. 10:158–164. 2013.PubMed/NCBI
|
|
24
|
Zhang ZY, Zhou ZQ and Zhou GW: Higher
efficacy of antiviral therapy after major hepatectomy in patients
with hepatitis B virus-related hepatocellular carcinoma of less
than 3 cm. Eur J Gastroenterol Hepatol. 26:1116–1124. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhong JH, Zhong QL, Li LQ and Li H:
Adjuvant and chemopreventive therapies for resectable
hepatocellular carcinoma: A literature review. Tumour Biol.
35:9459–9468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu LH, Li N, Shi J, Guo WX, Wu MC and
Cheng SQ: Does anti-HBV therapy benefit the prognosis of
HBV-related hepatocellular carcinoma following hepatectomy? Ann
Surg Oncol. 21:1010–1015. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan Q, Ni J, Zhang GL, Yao X, Yuan WB,
Zhou L and Zheng SS: Efficacy of postoperative antiviral combined
transcatheter arterial chemoembolization therapy in prevention of
hepatitis B-related hepatocellular carcinoma recurrence. Chin Med J
(Engl). 126:855–859. 2013.PubMed/NCBI
|
|
28
|
Zhu SL, Zhong JH, Ke Y, Xiao HM, Ma L,
Chen J, You XM and Li LQ: Comparative efficacy of postoperative
transarterial chemoembolization with or without antiviral therapy
for hepatitis B virus-related hepatocellular carcinoma. Tumour
Biol. 36:6277–6284. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ma SL, Lv Y and Jiang JH: Efficacy of
combined adjuvant transarterial chemoembolization and antiviral
therapy in patients with HBV-related hepatocellular carcinoma after
surgery. Tumour Biol. 36:7395–7396. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhong JH: Nucleos(t)ide analogue therapy
for HBV-related HCC after hepatic resection: Clinical benefits and
unanswered questions. Tumour Biol. 35:12779–12784. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang G, Lai EC, Lau WY, Zhou WP, Shen F,
Pan ZY, Fu SY and Wu MC: Posthepatectomy HBV reactivation in
hepatitis B-related hepatocellular carcinoma influences
postoperative survival in patients with preoperative low HBV-DNA
levels. Ann Surg. 257:490–505. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu X, Huang P, Tian H, Chen Y, Ge N, Tang
W, Yang B and Xia J: Role of lamivudine with transarterial
chemoembolization in the survival of patients with hepatocellular
carcinoma. J Gastroenterol Hepatol. 29:1273–1278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Toyoda H, Kumada T, Tada T, Sone Y and
Fujimori M: Transarterial chemoembolization for hepatitis B
virus-associated hepatocellular carcinoma: Improved survival after
concomitant treatment with nucleoside analogues. J Vasc Interv
Radiol. 23:317–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
